Project 1: DE86ER60407 This project funded since 1986 serves as a core project for cancer research throughout MSKCC, producing key radiotracers as well as basic knowledge about thel physics of radiation decay and imaging, for nuclear medicine applications to cancer diagnosis and therapy. In recent years this research application has broadened to include experiments intended to lead to an improved understanding of cancer biology and into the discovery and testing of new cancer drugs. 
3.
Radionuclide generator systems One key advancement resulting from this DOE project has been the development of an actinium-225 generator, allowing the production of the short-lived isotope bismuth-213 for alpha targeted radioimmunotherapy. This work resulted in the first clinical radioimmunotherapy trial using an alpha emitter in the World being performed at MSKCC with the 213 Bi-M195 antibody in patients with leukemia. This was made possible through DOE funded column development.
Medical Physics Advances which support biologic initiatives have been in several areas
including: imaging corrections methods for positron emitters, which release complex prompt photon spectra, e.g. iodine-124 and yttrium-86 that cannot be eliminated by timing or energy discrimination, patient specific radionuclide dosimetry using novel radionuclide therapy treatment planning systems, quantitative digital autoradiography, small animal stereotactic image registration techniques and most recently hypoxia imaging using a novel 124 I tracer iodoazomycin galactosidase( 124 I-IAZGP), which has led to the funding of a new NCI program project grant with a focus on non-invasive imaging of tumor hypoxia. 
Development of 5F11 sfv/avidin fusion, a novel anti-GD2 tetrameric antibody has been
accomplished through this collaboration and shown to target to GD2 expressing animal models. GD2 is an important antigen target that is expressed on pediatric brain tumor such as neuro-and medullo-blastoma, small cell lung carcinoma and melanoma. These studies dovetail with ongoing successful clinical radioimmunotherapy trials using the 131 I-labeled 3F8i and provide important pre-clinical information on methods to advance ongoing clinical pediatric therapy trials.
2. Successful PET imaging of Yttrium-86, Gallium-66, and Gallium-68 Several pre-clinical studies have been performed under this DOE funding demonstrating for the first time the feasibility of quantitative PET imaging to determine tumor uptake and for radionuclide dosimetry.
Gene directed labeling of T-cells using FIAU
The first work to use the reporter gene technology to successfully track human EBV lymphoma tumor injected into mice arose form this funded grant. This work allows for an improved specificity of tracking T-cells via a gene directed and selective uptake of the FIAU reporter probe. This advance will facilitate improved in vivo monitoring of adoptive immunotherapy, in which immune cells are prepared outside the body, and then administered to a patient for the purposes of therapy against a human tumor.
The objective accomplishments resulting from DOE funding at MSKCC is best summarized by the achievements in terms of the number of publications, NIH funded grants that utilize radiotracers 
